Menu
  • Find a Doctor
  • International Patients
  • Newsroom
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • Donate to The Barrow

    Robert Bowser, PhD

    Chairman, Neurobiology
    Professor, Neurology and Neurobiology (602) 406-8989

    Dr. Robert Bowser is an internationally-recognized leader in ALS research. He has contributed to pioneering efforts to discover and validate biomarkers for ALS. These biomarkers can be useful as diagnostic indicators of disease, predictors of disease progression, and also in determining the effectiveness of drugs in clinical trials. Dr. Bowser has extensive experience in the translation of basic science discoveries to the clinic to impact patient care.

    As director of the ALS Research Center, Dr. Bowser directs research to determine the underlying mechanisms of ALS, identify new targets for drug treatment, develop improved therapies for ALS, and lead clinical research studies performed in numerous medical centers throughout North America.

    Dr. Bowser is a graduate of Carnegie Mellon University and obtained his PhD from Yale University. He performed fellowship training at the Albert Einstein College of Medicine and was a faculty member at the University of Pittsburgh from 1994 to 2011, rising through the ranks to full professor. He joined the faculty at Barrow in 2011.

    Education & Training
    • Post-doctoral Fellowship, Pathology, Albert Einstein College of Medicine, 1992-1994
    • Phd, Yale University, 1992
    • BS, Carnegie Mellon University, 1987
    Professional Memberships
    • Society for Neuroscience
    • American Society for Investigative Pathology
    • American Association of Neuropathologists
    • New York Academy of Sciences
    • ALS Research Group
    • International Society for Biological and Environmental Repositories
    • American Association for the Advancement of Science
    • World Federation of Neurology Research Group on Motor Neuron Diseases
    Honors and Awards
    • Sheila Essey Award for ALS Research, 2015
    • NEALS NeuroBank Pioneer Award, 2015
    • Arizona Innovation Challenge Award, 2015
    • John and Betty VenDenburgh Chair of Neuromuscular Disease, 2012
    • Scientific Advisory Board, Northeast Amyotrophic Lateral Sclerosis Consortium, 2011
    • Guest Editor, International Journal of Molecular Sciences, 2010
    • Science Council, Association Francaise contre les Myopathies, 2009 – 2011
    • ALS Association “Walk to D’Feet ALS” Service Award, 2008
    • University of Pittsburgh Innovator Award, 2008
    • University of Pittsburgh Innovator Award, 2006
    • Pittsburgh Magazine “40 under 40” Award for young people shaping the region, 2005
    • ALS Association Lou Gehrig’s Challenge Award, 2004
    • University of Pittsburgh Chancellor’s Distinguished Public Service Award, 2003
    • ALS Association Public Service Award, 2002
    Selected Publications

    View complete list of publications on PubMed.

    1. Smith R, Myers K, Ravits J, Bowser R. Amyotrophic lateral sclerosis: Is the spinal fluid pathway involved in seeding and spread? Med Hypotheses. Nov 2015;85(5):576-583.
    2. Rutkove SB, Shefner JM, Bowser R, Benatar M. To travel or not to travel: The modern day struggle of the academic researcher. Ann Neurol. Nov 2015;78(5):667-669.
    3. Li Y, Collins M, Geiser R, Bakkar N, Riascos D, Bowser R. RBM45 homo-oligomerization mediates association with ALS-linked proteins and stress granules. Sci Rep. 2015;5:14262.
    4. Collins MA, An J, Peller D, Bowser R. Total protein is an effective loading control for cerebrospinal fluid western blots. J Neurosci Methods. Aug 15 2015;251:72-82.
    5. Collins MA, An J, Hood BL, Conrads TP, Bowser RP. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis. J Proteome Res. Nov 6 2015;14(11):4486-4501.
    6. Bakkar N, Kousari A, Kovalik T, Li Y, Bowser R. RBM45 Modulates the Antioxidant Response in Amyotrophic Lateral Sclerosis through Interactions with KEAP1. Mol Cell Biol. Jul 2015;35(14):2385-2399.
    7. Bakkar N, Boehringer A, Bowser R. Use of biomarkers in ALS drug development and clinical trials. Brain Res. May 14 2015;1607:94-107.
    8. Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo A, Rothstein JD, Consortium I, Drepper C, Sendtner M, Singleton AB, Taylor JP, Cookson MR, Restagno G, Sabatelli M, Bowser R, Chio A, Traynor BJ. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. May 2014;17(5):664-666.
    9. Ganesalingam J, An J, Bowser R, Andersen PM, Shaw CE. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener. Mar 2013;14(2):146-149.
    10. Collins M, Riascos D, Kovalik T, An J, Krupa K, Krupa K, Hood BL, Conrads TP, Renton AE, Traynor BJ, Bowser R. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Acta Neuropathol. Nov 2012;124(5):717-732.